Molecular Analysis for Therapy Choice (MATCH)
This phase II trial studies how well treatment that is directed by genetic testing works in
patients with solid tumors or lymphomas that have progressed following at least one line of
standard treatment or for which no agreed upon treatment approach exists. Genetic tests look
at the unique genetic material (genes) of patients'' tumor cells. Patients with genetic
abnormalities (such as mutations, amplifications, or translocations) may benefit more from
treatment which targets their tumor''s particular genetic abnormality. Identifying these
genetic abnormalities first may help doctors plan better treatment for patients with solid
tumors, lymphomas, or multiple myeloma.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.